/
/
Ninlaro Extends Survival as Maintenance Therapy for Transplant Ineligible Patients
Ninlaro Extends Survival as Maintenance Therapy for Transplant Ineligible Patients image
Ninlaro Extends Survival as Maintenance Therapy for Transplant Ineligible Patients
Posted Nov 15, 2019

Phase III results of a recent study (TOURMALINE-MM4) show that Ninlaro (ixazomib) can prolong survival when used as maintenance therapy for multiple myeloma patients who are not fit enough to receive a stem cell transplant. Ninlaro is in a class of drugs called proteasome inhibitors.

Revlimid (lenalomide), an immumomodulator, is commonly used in today's myeloma clinic as maintenance therapy. The results of this study show that Ninlaro as an additional maintenance therapy option may also be helpful. 

Study authors reviewed data from four different Ninlaro studies for 706 newly diagnosed myeloma patients where they received induction therapy with once or twice-weekly ixazomib plus one of the following combinations:

  • Lenalidomide/dex (IRd)
  • Melphalan/prednisone (IMP)
  • Cyclophosphamide/dex (Icd)

 

Patients were then given only ixazomib as maintenance therapy until disease progression. A total of 121 patients achieved stable disease or better after their initial myeloma treatment: 

  • Once weekly IRD = 25 patients
  • Twice weekly IRD - 18 patients
  • Once or twice weekly IMP = 35 patients
  • Weekly ICD  = 43 patients

 

About 22% of the myeloma patients had a complete response after their initial therapy. A total of 28 patients (23%) improved their response during maintenance. After maintenance therapy, that number grew to 35%. Study authors noted: 

“There is increasing evidence for the clinical benefit of long-term, continuous therapy in patients with newly diagnosed multiple myeloma, irrespective of whether they undergo autologous stem cell transplantation.” 

Maintenance therapy is typically a lower dose of medication for an extended period of time and for many myeloma patients, it can extend their remissions considerably. We'll learn more at the upcoming ASH 2019 meeting in Orlando about this convenient and oral option. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811